Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ADK | P55263 | 1/20 | 0.36 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2991341 | 1.00 | TLR7 (0.38) | TLR7HIF1APDE10ATDP1ADK | |
| SCHEMBL2993933 | 0.84 | HIF1A (0.36) | HIF1AP2RY1 | |
| SCHEMBL2993931 | 0.84 | HIF1A (0.36) | HIF1AP2RY1 | |
| SCHEMBL11986893 | 0.84 | POLB (0.47) | P2RY1 | |
| SCHEMBL1140779 | 0.84 | HIF1A (0.42) | HIF1AP2RY1 | |
| SCHEMBL7215063 | 0.84 | POLB (0.47) | P2RY1 | |
| SCHEMBL30197148 | 0.84 | POLB (0.47) | P2RY1 | |
| SCHEMBL30944277 | 0.84 | HIF1A (0.40) | HIF1AP2RY1 | |
| SCHEMBL21317437 | 0.84 | POLB (0.47) | P2RY1 | |
| SCHEMBL15152575 | 0.83 | ADK (0.42) | TLR7PDE10ATDP1ADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501931-B2 | Convertible nucleoside derivatives | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2013-08-06 | — | — | US | disclosed |
| US-20100179312-A1 | CONVERTIBLE NUCLEOSIDE DERIVATIVES | LAKSHMAN MAHESH K | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179312-A1 | CONVERTIBLE NUCLEOSIDE DERIVATIVES | PNP, NUDT1, NUDT14 | TLR7 544/4885HIF1A 3959/4885PDE10A 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.